Molecular Landscape of Microvascular Inflammation in Kidney Allografts
This study helps us understand why some transplanted kidneys develop inflammation in their tiny blood vessels. This inflammation, called microvascular inflammation, is a big problem that can lead to the kidney being rejected. Doctors recently updated how they describe these changes, but we still don't fully understand what causes them, making it hard to develop good treatments. Researchers are using advanced lab techniques to examine kidney samples from people who have had a kidney transplant. They want to map out the different features of this inflammation at a very detailed level. By understanding these features better, they hope to find new ways to target and treat this inflammation, potentially helping transplanted kidneys last longer.
At a glance
What is this study about?
When someone receives a kidney transplant, their body's immune system might sometimes see the new kidney as foreign and try to attack it. This attack can lead to something called 'rejection.' A common and serious type of rejection affects the tiny blood vessels within the transplanted kidney, causing inflammation. This is known as microvascular inflammation, and it's a major reason why transplanted kidneys might not work as well or might fail over time.
Doctors have recently updated their guidelines (called the Banff classification) on how to identify and describe these changes in the blood vessels. However, even with these new guidelines, we don't fully understand why some people's kidneys develop this inflammation or what exactly is happening at a microscopic level. This lack of detailed understanding makes it difficult to create new and effective treatments, which is why research like this is so important.
In this study, researchers will be looking very closely at kidney samples. They will use a range of special tests and advanced technologies to create a detailed 'map' of the inflammation in these tiny blood vessels. They want to see how these changes differ in various situations. By understanding these differences, they hope to identify specific targets that could lead to new, more effective medications to prevent or treat rejection, ultimately helping transplanted kidneys work better and last longer for patients.
Key takeaways
- Aims to understand kidney transplant rejection better.
- Uses existing kidney tissue samples, no new procedures for patients.
- Focuses on inflammation in tiny blood vessels within transplanted kidneys.
- Could help develop new treatments for kidney rejection in the future.
- Participation involves no direct patient contact or actions.
Who may be eligible?
This study is looking for adults aged 18 to 100 who have received a kidney transplant. To be considered, you must have had at least one kidney biopsy that was checked using the most recent medical guidelines (Banff 2022 classification), whether or not signs of inflammation were found.
There are certain reasons why someone might not be able to participate. For example, if your kidney biopsy wasn't clear enough or if some important medical details about your biopsy, antibodies (donor-specific antibody status), or a specific test result (C4d staining) are missing, you wouldn't be able to join.
Also, if your biopsy shows signs of damage from the kidney not getting enough blood flow before or during the transplant (ischemia-reperfusion), or if you had other organs transplanted at the same time as your kidney, or a kidney transplant after another organ transplant (like a heart or liver), you would not be eligible.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you an adult (18-100 years old)?
- Have you had a kidney transplant?
- Have you had at least one kidney biopsy?
- Was your biopsy checked using the latest medical guidelines (Banff 2022)?
- Did you not have other organ transplants at the same time as your kidney?
What does participation involve?
This study does not involve any medical interventions, new treatments, or procedures. Instead, researchers will be using existing kidney tissue samples that were taken during routine care (like a biopsy) and analysed in the lab. You will not need to make any extra visits or take any medication for this study. Your participation simply means that your past biopsy samples will be used to help researchers understand kidney rejection better. There will be no follow-up appointments or long-term commitments required from you.
Potential risks and benefits
Locations (3)
- Kidney Transplant Department, Saint-Louis Hospital, Assistance Publique - Hôpitaux de ParisVerified postcodeParis, France· Recruiting
- Kidney Transplant Department, Necker Hospital, Assistance Publique - Hôpitaux de ParisVerified postcodeParis, France· Recruiting
- Bichat Hospital, Assistance Publique - Hôpitaux de ParisVerified postcodeParis, France· Recruiting
Common questions
What is 'microvascular inflammation'?
It's when tiny blood vessels in a transplanted kidney get inflamed, which can lead to the kidney being rejected.
Will I need to do anything if I take part?
No, this study uses existing kidney samples. You won't need to attend extra appointments, take medicine, or have any new procedures.
What is the study trying to achieve?
It aims to better understand why kidney transplants sometimes get rejected due to inflammation, hoping to find new and more effective treatments.
Will I get any specific treatment as part of this study?
No, this is an observational study looking at existing information. It does not involve giving any new treatments.
Who is funding this research?
The information provided does not specify the funding source for this particular study.
How to find out more
Alexandre Loupy, MD PhD
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.